Literature DB >> 7658216

Carbon-11-acetate PET imaging in renal disease.

P Shreve1, P C Chiao, H D Humes, M Schwaiger, M D Gross.   

Abstract

UNLABELLED: The purpose of this study was to investigate the use of [1-11C]acetate as a metabolic tracer for renal imaging in human subjects.
METHODS: Eighteen patients underwent dynamic PET imaging of the kidneys after intravenous bolus injection of 10-20 mCi [1-11C]acetate. Time-activity curves of renal parenchyma tracer activity were fitted to a two-compartment model using direct arterial blood sampling for the arterial input function.
RESULTS: Renal uptake of [1-11C]acetate is prompt and high target-to-background ratios are achieved even in the presence of markedly reduced renal function. Carbon-11-acetate is cleared from the renal parenchyma without any urinary excretion and the rate of clearance is comparable to myocardial clearance rates. Among normal subjects, K1, ranged from 0.653 to 1.37 ml/min-g, and was reduced to as low as 0.363 ml/min-g in severe renal disease (serum creatinine greater than 5 mg/dl), while k2 ranged from 0.114 to 0.166 min-1 among normal subjects and was reduced to as low as 0.053 min-1 in severe renal disease. Kinetic parameters K1 and k2 were both reduced in the presence of intrinsic renal disease or significant renal artery stenosis. Renal cell carcinoma demonstrated similar uptake of [1-11C]acetate, but substantially reduced the rate of clearance compared to normal and diseased non-neoplastic renal tissue, allowing for ready differentiation of renal cell carcinoma from non-neoplastic renal tissue on images acquired beyond 10 min of tracer administration.
CONCLUSION: Carbon-11-acetate is a promising physiologic tracer for the study of renal disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658216

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  32 in total

1.  Renal oncocytoma on 1-11C acetate positron emission tomography: Case report and literature review.

Authors:  Jabi Shriki; Venkatesh Murthy; Jeffrey Brown
Journal:  Mol Imaging Biol       Date:  2006 Jul-Aug       Impact factor: 3.488

Review 2.  [Impact of nuclear medicine imaging techniques for lymph node surgery].

Authors:  L S Freudenberg; G Holl; S P Müller; S J Rosenbaum-Krumme; J Sciuk; A Bockisch
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

Review 3.  Targeted therapies in renal cell cancer: recent developments in imaging.

Authors:  Astrid A M van der Veldt; Martijn R Meijerink; Alfons J M van den Eertwegh; Epie Boven
Journal:  Target Oncol       Date:  2010-07-14       Impact factor: 4.493

4.  PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.

Authors:  Jean-Noël Talbot; Fabrice Gutman; Laetitia Fartoux; Jean-Didier Grange; Nathalie Ganne; Khaldoun Kerrou; Dany Grahek; Françoise Montravers; Raoul Poupon; Olivier Rosmorduc
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-27       Impact factor: 9.236

5.  11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation.

Authors:  Esther Mena; Baris Turkbey; Haresh Mani; Stephen Adler; Vladimir A Valera; Marcelino Bernardo; Vijay Shah; Thomas Pohida; Yolanda McKinney; Gideon Kwarteng; Dagane Daar; Maria L Lindenberg; Philip Eclarinal; Revia Wade; W Marston Linehan; Maria J Merino; Peter A Pinto; Peter L Choyke; Karen A Kurdziel
Journal:  J Nucl Med       Date:  2012-02-17       Impact factor: 10.057

6.  Tuberculous scar tumour detected by dual tracer positron emission-computerised tomography in a tuberculous endemic area.

Authors:  Chee-Kin Hui
Journal:  Malays J Med Sci       Date:  2014 Nov-Dec

7.  1-[11C]-acetate PET imaging in head and neck cancer--a comparison with 18F-FDG-PET: implications for staging and radiotherapy planning.

Authors:  Aijun Sun; Jens Sörensen; Mikael Karlsson; Ingela Turesson; Bengt Langström; Per Nilsson; Lena Cederblad; Jan Bertling; Katrine Riklund; Silvia Johansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

8.  Future direction of renal positron emission tomography.

Authors:  Zsolt Szabo; Jinsong Xia; William B Mathews; Phillip R Brown
Journal:  Semin Nucl Med       Date:  2006-01       Impact factor: 4.446

Review 9.  Novel tracers and their development for the imaging of metastatic prostate cancer.

Authors:  Andrea B Apolo; Neeta Pandit-Taskar; Michael J Morris
Journal:  J Nucl Med       Date:  2008-11-07       Impact factor: 10.057

10.  11C-acetate PET imaging of lung cancer: comparison with 18F-FDG PET and 99mTc-MIBI SPET.

Authors:  Kotaro Higashi; Yoshimichi Ueda; Ichiro Matsunari; Yuko Kodama; Ryosuke Ikeda; Katsuyuki Miura; Suzuka Taki; Takahiro Higuchi; Hisao Tonami; Itaru Yamamoto
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-10-22       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.